Haemonetics financials
$105.80+0.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 28 | FY25 Mar 29 | FY24 Mar 30 | FY23 Apr 1 | FY22 Apr 2 | FY21 Apr 3 | FY20 Mar 28 | FY19 Mar 30 | FY18 Mar 31 | FY17 Apr 1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.5M | $988.5M | $967.6M | $903.9M | $886.1M |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M | $397.8M | $484.5M | $417.5M | $411.9M | $378.5M |
| Gross margin | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.2% | 45.6% | 42.7% |
| Operating income | $156.7M | $221.8M | $164.9M | $155.7M | $71.1M | $89.8M | $95.3M | $83.5M | $56.2M | -$19.4M |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M | $79.5M | $76.5M | $55.0M | $45.6M | -$26.3M |
| Net margin | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | −3.0% |
| Diluted EPS | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 |
| EBITDA | $355.0M | $339.8M | $272.5M | $248.0M | $168.9M | $174.1M | $256.2M | $193.0M | $145.4M | $128.9M |
| Operating cash flow | $293.2M | $181.7M | $181.8M | $273.1M | $172.3M | $108.8M | $158.2M | $159.3M | $220.3M | $159.7M |
| Free cash flow | $208.6M | $121.3M | $115.5M | $162.9M | $75.8M | $71.8M | $109.5M | $40.3M | $145.6M | $83.6M |
| Diluted shares | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M | 51.3M | 51.8M | 52.9M | 53.5M | 51.5M |
Balance sheet
| Period end | Mar 28 | Mar 29 | Mar 30 | Apr 1 | Apr 2 | Apr 3 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $245.4M | $306.8M | $178.8M | $284.5M | $259.5M | $192.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.22B | $1.22B | $807.8M | $765.9M | $773.6M | $707.6M |
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B |
| Total liabilities | $1.60B | $1.63B | $1.24B | $1.12B | $1.11B | $1.09B |
| Shareholders' equity | $796.3M | $820.8M | $960.0M | $818.0M | $749.4M | $731.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology